Fulgent Genetics, Inc.

Name: Fulgent Genetics, Inc. standardized financial statements, quarterly
Creator: Listed

FLGTNasdaqCIK 1674930HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$85.4m, Q2 FY2026

Operating income−$36.1m, Q2 FY2026

Net income−$29.5m, Q2 FY2026

Fulgent Genetics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	84.7	70.5	64.5	71.0	71.7	76.2	73.5	81.8	84.1	83.3	71.1	85.4
Cost of revenue	$m	44.8	45.3	42.4	44.5	45.0	44.4	45.1	47.4	48.6	50.8	49.6	59.7
Gross profit	$m	39.8	25.2	22.1	26.5	26.8	31.8	28.3	34.4	35.5	32.6	21.5	25.7
Research and development	$m	10.0	12.0	11.4	13.5	11.8	12.1	12.4	13.5	13.9	14.2	14.2	14.6
Operating income	$m	0.2	(151)	(21.8)	(18.9)	(17.1)	(16.1)	(19.8)	(19.7)	(15.4)	(36.2)	(34.6)	(36.1)
Interest expense	$m	0.0	0.2	(0.2)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Income tax	$m	20.3	(10.9)	(0.3)	(2.1)	(3.8)	(1.9)	0.2	(2.3)	(0.7)	(5.6)	(0.7)	0.0
Net income	$m	(13.1)	(128)	(13.5)	(8.7)	(14.6)	(5.9)	(11.5)	(19.0)	(6.6)	(23.4)	(24.8)	(29.5)
Diluted EPS	$ per share	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Basic EPS	$ per share	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Balance sheet

Cash and equivalents$26.3m, Q2 FY2026

Shareholders' equity$1.00bn, Q2 FY2026

Fulgent Genetics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	84.1	97.5	54.7	65.1	58.0	55.1	67.3	87.9	118	50.2	23.4	26.3
Current assets	$m	550	508	387	399	327	354	417	429	507	550	479	455
Total assets	$m	1,358	1,235	1,230	1,232	1,234	1,220	1,206	1,200	1,215	1,214	1,156	1,089
Current liabilities	$m	61.4	73.0	75.9	75.8	74.0	72.9	65.9	71.3	72.4	85.0	90.1	71.8
Total liabilities	$m	96.6	102	103	103	98.9	90.8	83.0	88.2	93.8	107	112	93.2
Shareholders' equity	$m	1,259	1,136	1,130	1,133	1,138	1,133	1,127	1,117	1,126	1,112	1,050	1,002

Cash flow

Operating cash flow−$23.8m, Q2 FY2026

Capital expenditure$3.9m, Q2 FY2026

Share repurchases$23.8m, Q2 FY2026

Fulgent Genetics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	10.2	14.9	7.3	4.3	(15.5)	25.0	(4.4)	(30.2)	11.1	(78.1)	7.1	(23.8)
Capital expenditure	$m	4.9	3.1	4.1	12.9	19.5	3.8	4.7	6.8	6.1	5.0	5.2	3.9
Share repurchases	$m	not reported	22.9	0.2	0.0	0.0	0.0	8.7	2.2	0.0	0.0	40.1	23.8

Diluted shares (weighted)28.00m, Q2 FY2026

Fulgent Genetics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	30.9	29.5	29.8	30.0	29.8	30.1	30.4	30.8	30.5	30.7	30.9	28.0

Shares outstanding: 27.52m at Jul 27, 2026, from the cover of the 10-Q filed Jul 30, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.